ABT's latest 8-K is categorized as other events. The cached primary document did not contain a substantive passage that the deterministic extractor could cite.
COMPANY OVERVIEW · SOURCE-BACKED
Abbott Laboratories
ABTCompany evidence profile
Historical market context and recent SEC disclosures for Abbott Laboratories. This view uses the current local evidence snapshot.
- Latest adjusted close
- $103.70Observed 2026-10-23
- Return gap vs SPY
- -87.92021-10-25 to 2026-10-23
- Filings in snapshot
- 5Prices 1980-03-17 to 2026-10-23
Price field: vendor-adjusted closeSEC EDGAR company recordCIK 0000001800
THE BRIEF
Start here, then verify below.
Three statements, each labelled by what kind of statement it is. Every number in them is linked to its source further down the page.
Over the selected historical period, ABT returned -9.5% with a maximum drawdown of -39.6%. These are historical observations, not a forecast.
This local snapshot covers SEC disclosures, latest-restated annual Company Facts when available, and adjusted daily prices. It does not establish valuation, future return, or an investment recommendation.
Generated: deterministic_fallback · Historical observations, not forecasts.
FILED RESULTS
What the latest financial report says
Quarterly figures as filed in the 10-Q for the period ending 2026-06-30, filed 2026-07-28. Read from one filing, so the period and the accounting concept always match the number.
Report found, figures not extractable
The filing was located but no figure matched the reporting period and accounting concept this page requires, so nothing is displayed rather than an approximate one.
Consolidated figures as reported. Accounting treatment and business mix differ between companies, and a filed result is not a forecast.
HISTORY AND RISK
What this has done, and how roughly
Adjusted daily prices over the selected period, against SPY. SPY is an exchange-traded fund tracking the S&P 500.
ABTSPYAdjusted daily closes
Ending value$9,050From $10,000 invested, 2021-10-25 to 2026-10-23
Return gap vs SPY, in percentage points-87.9ABT -9.5% · SPY +78.4%
Total return-9.5%2021-10-25 to 2026-10-23
Annualised return-2%Compound rate over the period shown
Annualised volatility23.1%Daily returns, annualised
Maximum drawdown-39.6%Trough 2026-05-11
Beta to SPY0.49Sensitivity to the benchmark's moves
Correlation with SPY0.371,255 matched sessions
What that felt likeThe worst peak-to-trough fall over this period was -39.6%, and the worst single session was -10%. Both already happened; neither bounds what comes next.
Only this section follows the benchmark selector. The brief, filing reactions and Ask evidence stay on SPY; this chart is showing SPY.
Past return and risk are observations about a period that is over. They are not a forecast, and nothing here is investment advice.
PRIMARY DISCLOSURES
What was filed
SEC checked 2026-10-24
The filings themselves, with what the company disclosed kept apart from what this project measured about it.
8-KOther events2026-10-21 17:19+1.3% after filing
- Other events
- Financial statements and exhibits
No passage could be extracted deterministically from the cached primary document, so none is quoted.
Against the prior comparable filing
Compared with the filing accepted 2026-04-18: 0 changed, 1 added, 1 removed.
Added
English, as filed
false 0000001800 Common Shares, Without Par Value ABT 0000001800 2026-10-21 2026-10-21 0000001800 us-gaap:CommonStockMember exch:XCHI 2026-10-21 2026-10-21 0000001800 us-gaap:CommonStockMember exch:XNYS 2026-10-21 2026-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
Removed
8-KResults of operations (earnings)2026-10-21 15:36+1.3% after filing
- Results of operations (earnings)
- Financial statements and exhibits
Quoted from the filing
English, as filed
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.
Source passage
English, as filed
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
Source passage
English, as filed
These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance.
Source passage
Against the prior comparable filing
Compared with the filing accepted 2026-07-16: 1 changed, 1 added, 1 removed.
Changed · 67% text match
English, as filed
abt-20261021 0000001800 FALSE New York Stock Exchange CHX 0000001800 2026-10-21 2026-10-21 0000001800 exch:XNYS 2026-10-21 2026-10-21 0000001800 exch:XCHI 2026-10-21 2026-10-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
Added
English, as filed
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
8-KRegulation FD disclosure2026-08-21 00:33+2.3% after filing
- Regulation FD disclosure
- Other events
- Financial statements and exhibits
Quoted from the filing
English, as filed
On August 20, 2026, rather than continuing to appeal or paying approximately $600 million (representing the Gill judgment plus accrued interest to date), Abbott entered into agreements to resolve the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million.
Source passage
English, as filed
In a July 2024 Missouri state court trial, a jury awarded a plaintiff (“ Gill ”) $495 million in damages, which Abbott appealed to the Missouri Court of Appeals in December 2024.
Source passage
English, as filed
These agreements are a compromise of disputed claims and not in any way an admission of liability.
Source passage
Numbers in the filing
- $600 million
- $670 million
- $495 million
Against the prior comparable filing
Compared with the filing accepted 2022-02-18: 1 changed, 10 added, 9 removed.
Changed · 81% text match
English, as filed
false 0000001800 Common Shares, Without Par Value ABT 0000001800 2026-08-20 2026-08-20 0000001800 us-gaap:CommonStockMember exch:XCHI 2026-08-20 2026-08-20 0000001800 us-gaap:CommonStockMember exch:XNYS 2026-08-20 2026-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
Added
English, as filed
On August 20, 2026, rather than continuing to appeal or paying approximately $600 million (representing the Gill judgment plus accrued interest to date), Abbott entered into agreements to resolve the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million.
8-KResults of operations (earnings)2026-07-16 15:36-0.5% after filing
- Results of operations (earnings)
- Financial statements and exhibits
Quoted from the filing
English, as filed
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.
Source passage
English, as filed
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal reserves, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
Source passage
English, as filed
These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance.
Source passage
Against the prior comparable filing
Compared with the filing accepted 2026-04-16: 1 changed, 1 added, 1 removed.
Changed · 71% text match
English, as filed
abt-20260716 0000001800 FALSE New York Stock Exchange CHX 0000001800 2026-07-16 2026-07-16 0000001800 exch:XCHI 2026-07-16 2026-07-16 0000001800 exch:XNYS 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
Added
English, as filed
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal reserves, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
8-KDirector or principal officer change2026-04-28 00:06+0.0% after filing
- Director or principal officer change
- Fiscal year or bylaw amendment
- Shareholder vote results
- Financial statements and exhibits
Quoted from the filing
English, as filed
The 2026 Program, which is administered by the Compensation Committee of Abbott’s Board of Directors, permits Abbott to grant nonqualified stock options, restricted stock awards, restricted stock units, performance awards, and other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards) to non-employee directors and employees of Abbott and its subsidiaries.
Source passage
Against the prior comparable filing
Compared with the filing accepted 2025-12-13: 0 changed, 12 added, 2 removed.
Added
English, as filed
The 2026 Program, which is administered by the Compensation Committee of Abbott’s Board of Directors, permits Abbott to grant nonqualified stock options, restricted stock awards, restricted stock units, performance awards, and other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards) to non-employee directors and employees of Abbott and its subsidiaries.
Added
English, as filed
On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.
Earlier filings
Each with the move on the first eligible session afterwards, measured against the benchmark. A measurement of magnitude, not a cause.
- 2026-03-23Other events-0.3% on 2026-03-24Source filing
- 2026-04-16Results of operations (earnings)+0.7% on 2026-04-17Source filing
- 2026-04-18Other events-0.5% on 2026-04-20Source filing
- 2026-04-28Director or principal officer change+0.0% on 2026-04-28Source filing
- 2026-07-16Results of operations (earnings)-0.5% on 2026-07-17Source filing
- 2026-08-21Regulation FD disclosure+2.3% on 2026-08-21Source filing
- 2026-10-21Results of operations (earnings)+1.3% on 2026-10-22Source filing
- 2026-10-21Other events+1.3% on 2026-10-22Source filing
EVENTS AND WHAT IS NEXT
What happened, and what to watch
Event items are published headlines and filing index entries, linked to their source. They are not analysis, and the feed is not a trading signal.
GROUNDED RESEARCH
Ask about this evidence
Questions are answered from this company's evidence packet alone. Citations and number literals are checked against that packet before an answer is shown, and an answer that fails the check is withheld rather than displayed.
No investment advice, price target or directional forecast is produced, and a question asking for one is refused.